Transcription strikes back: clinical utility of lung adenocarcinoma subtypes.

Transcription strikes back: clinical utility of lung adenocarcinoma subtypes.
Clin Cancer Res. 2020 Dec 16;:
Authors: Skoulidis F
Abstract
Using transcriptional profiling, three robust subtypes of non-squamous NSCLC are defined, independently of initiating oncogenic driver events. Subtype-specific differential sensitivity to MEK1/2 inhibitors is reported and an interaction between the mucinous subtype, STK11/LKB1 genomic alterations and inferior clinical outcomes with atezolizumab in the OAK clinical trial is identified.
PMID: 33328344 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 16, 2020 Category: Cancer & Oncology Authors: Skoulidis F Tags: Clin Cancer Res Source Type: research